Exploring perioperative treatment for non-small cell lung cancer patients harboring EGFR mutation: a real-world multicenter cohort study
The combination of immunotherapy and chemotherapy as neoadjuvant treatment demonstrated a promising pathological response among patients with <i>EGFR</i>-mutant NSCLC.
Authors
- Y X Zhou
- X. Pu
- Chao Zhou (ORCID: https://orcid.org/0000-0002-9443-6707)
- W H Jiang
- Baihua Zhang (ORCID: https://orcid.org/0000-0002-7941-9052)
- B. Chen
- Rui Meng
- Zihan Wei (ORCID: https://orcid.org/0000-0003-1734-3643)
- Juan Li (ORCID: https://orcid.org/0000-0002-6141-0762)
- Xiang Yan
- Min Li
- Fang Wu
- Lin Wu
- Liang Zeng
- Guanming Jiang
Institutions
- Union Hospital (HK)
- Central South University (CN)
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- China-Japan Friendship Hospital (CN)
- Hunan Provincial Center for Disease Control and Prevention (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Hunan Cancer Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Xiangya Hospital Central South University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-962
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00